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Abstract  
 
Acute myeloid leukemia (AML) is characterized by the accumulation of immature 
blood cell precursors in the bone marrow. Pharmacologically overcoming the 
differentiation block in this condition is an attractive therapeutic avenue, which 
has only achieved success in a subtype of AML, acute promyelocytic leukemia 
(APL). Attempts to emulate this success in other AML subtypes have thus far 
been unsuccessful. Autophagy is a conserved protein degradation pathway with 
important roles in mammalian cell differentiation, particularly within the 
hematopoietic system. In this study we demonstrate the functional importance 
of autophagy in APL cell differentiation. We show that autophagy is increased 
during ATRA-induced granulocytic differentiation of the APL cell line NB4, and 
that this is associated with increased expression of LC3-II and GATE-16 proteins 
involved in autophagosome formation. Autophagy inhibition, using either drugs 
(chloroquine/3-methyladenine) or short-hairpin (sh)RNA targeting the essential 
autophagy gene ATG7, attenuates myeloid differentiation. Importantly, we show 
that enhancing autophagy promotes ATRA-induced granulocytic differentiation 
of an ATRA-resistant derivative of the non-APL AML HL60 cell line (HL60-Diff-R). 
These data support the development of strategies to stimulate autophagy as a 
novel approach to promote differentiation in AML.  
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Introduction 
The term ‘acute myeloid leukemia’ (AML) describes a heterogeneous group of 
clonal disorders of hematopoietic progenitor cells, all of which are characterized 
by the accumulation of immature blood cell precursors in the bone marrow and 
peripheral circulation. In addition to environmentally leukemogenic factors, a 
complex interplay of cytogenetic, genetic and epigenetic abnormalities 
contributes to AML pathogenesis, conferring on malignant cells an increased 
proliferation rate, resistance to apoptosis and a differentiation block [1]. AML is 
the most common acute leukemia in adults, with an incidence that increases with 
age. The MRC AML trials report an overall survival of 47% for patients under 60 
years and 20% for those above 60 years [2].  These figures highlight that despite 
advances in molecular understanding of the condition, there is a need for 
improved and tolerable therapeutic strategies. ‘Differentiation therapy’ 
exploiting pharmacologic override of the cellular differentiation block observed 
in AML, is one attractive strategy with a favorable toxicity profile. Success with 
this approach has been achieved with the use of all-trans-retinoic acid (ATRA) 
for the treatment of acute promyelocytic leukemia (APL) [3].   
 APL is a distinct form of AML, accounting for approximately 10% of cases. 
It is distinguished by a characteristic morphology, a potentially fatal coagulation 
defect at clinical presentation and chromosomal translocations involving the 
retinoid acid receptor alpha (RARα) gene on chromosome 17 [3]. At least nine 
driver translocations have been identified, with the most common being at 
t15;17, which fuses the promyelocytic leukemia (PML) gene with RARα [3]. The 
resultant PML-RARα fusion oncoprotein represses transcription and blocks 
granulocyte differentiation at the promyelocyte stage [3]. Therapeutic doses of 
ATRA, a physiologically active retinoid, restore normal differentiation through 
two distinct mechanisms: (i) de-repression of transcription [4] and (ii) 
degradation of the PML-RARα oncoprotein [5, 6]. Arsenic trioxide (ATO) is a 
second differentiating agent that has now been incorporated into the treatment 
of APL. When administered in combination with ATRA, ATO eliminates the need 
for cytotoxic chemotherapy in the treatment of low to intermediate-risk APL [7]. 
Interestingly, ATO also increases the degradation of the PML-RARα protein [8], 
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and this proteolysis is now thought to be critical for eradicating APL leukemia-
initiating cells (LICs) and achieving long-term cures [5, 9]. 
 Autophagy is a degradative cellular process ubiquitously observed across 
the eukaryotic hierarchy. It allows the disposal of aged, redundant or damaged 
proteins, aggregates and organelles without steric limitation [10]. Cell contents 
targeted for autophagic degradation are sequestered within double-membraned 
autophagic vesicles known as ‘autophagosomes’, which are subsequently 
delivered to lysosomes and their contents degraded by resident proteases and 
hydrolases [11]. At a molecular level, autophagy is mediated by a family of 
AuTophaGy-related (ATG) proteins, which are sequentially recruited to the 
developing autophagosome membrane [12]. Membrane elongation is specifically 
dependent on two ubiquitination-like reactions: (i) the formation of an ATG5-
ATG12 conjugate and (ii) the conjugation of phosphatidylethanolamine (PE) to 
the ATG8 homologues LC3, GATE-16 and GABARAP. These lipidated proteins are 
then incorporated into and stabilize autophagic vesicles at different stages of 
maturation [11, 13, 14]. Both conjugation reactions are catalyzed by the E1 ligase 
ATG7 – thought to be an essential component of autophagy machinery [11]. 
 As a pathway involved in protein turnover, autophagy plays an intrinsic 
role in mammalian development and differentiation [13, 15]. Within the 
hematopoietic system, autophagy is specifically involved in organelle clearance 
during reticulocyte differentiation [15], lymphocyte differentiation [15] and 
plasma cell differentiation [16]. In addition, conditional hematopoietic cell 
deletion of Focal adhesion kinase (FAK) family interacting protein FIP200 – a key 
protein involved in autophagy activation, results in severe anemia [17], while 
ATG7 deletion leads to a fatal myeloproliferation resembling AML [18] - 
suggesting that autophagy may also be integral to normal myeloid differentiation. 
Through poorly characterized mechanisms, both ATRA and ATO have been 
shown to induce autophagy in APL cells [19-22]. This induction is thought to 
contribute to proteolysis of the PML-RARα oncoprotein [20, 22], similar to the 
mechanism by which imatinib-induced autophagy degrades the BCR-ABL 
oncoprotein in chronic myeloid leukemia (CML) [23]. 
We investigated the role of autophagy in ATRA-mediated granulocytic 
differentiation of APL cells. We confirm that autophagy is upregulated upon 
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ATRA treatment and demonstrate induction of ATG8 homologues LC3 and GATE-
16. Furthermore, we show that inhibition of autophagy with either drugs or 
targeted ATG7 knockdown attenuates APL cell differentiation. In addition, we 
show that pharmacologic autophagy induction facilitates the ATRA-mediated 
differentiation of non-APL, ATRA-resistant HL60-Diff-R AML cells, suggesting 
that targeting autophagy may represent a means of re-establishing 
differentiation in this aggressive cancer. 
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Materials and Methods 
 
Cell lines & culture  
NB4 cells were a gift from Prof. Estelle Duprez (INSERM, France). A 
differentiation-resistant variant of HL60 cells, HL60-Diff-R (HL60 genotype 
confirmed by LGC standards), were a gift from Prof. Tom Cotter (UCC, Ireland). 
Cells were maintained at 37°C, 5% CO2 in RPMI 1640 (Sigma, Ireland R8758), 
10% heat-inactivated fetal calf serum (Sigma F7524) and 1% 
Penicillin/Streptomycin (Gibco Ireland 15070-063). Cells were seeded at 2 x 105 
cells/ml prior to treatment.  
 
Primary APL cells 
Following local ethics committee approval and informed consent, peripheral 
blood samples were obtained from two patients newly-presenting with APL. 
Whole samples were gradient-separated using Histopaque-1077 (Sigma 10771) 
and mononuclear cells were extracted comprising a predominantly malignant 
population.  
 
Drug treatments 
ATRA (Sigma R2625) was diluted from a 1 mM stock in 100% ethanol. 
Lysosomal function was inhibited with E64d (Sigma E8640) and pepstatin A 
methyl ester (Calbiochem 516485). Autophagy was inhibited with chloroquine 
(Sigma C6628) and 3-methyladenine (3-MA) (Sigma M9281). Autophagy was 
induced with lithium chloride (Sigma L9650) and rapamycin (Sigma R8781). 
 
ATG7 knockdown 
pLKO.1 plasmid vectors expressing small hairpin (sh)RNAs targeting human 
ATG7 were purchased from Sigma (TRCN0000007584=shATG7_1 and 
TRCN0000007587=shATG7_2). Vectors were transfected into HEK293T cells 
along with lentiviral packaging plasmids pCMVΔ8.9 and pVSVG using 
Lipofectamine 2000 (Invitrogen 11668). An off-target scrambled vector was 
transfected as a control (shSCR). Cells were replenished with fresh media 
following overnight recovery and allowed to produce lentivirus for 48 hours. 
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Lentivirus was harvested by filtering the HEK293T culture supernatant through 
0.45 μm filters and supplementing with polybrene. NB4 cells were transduced 
with viral supernatant in a 1:1 ratio with 2x growth medium. Transduced cells 
were selected with puromycin (2 μg/mL) for 10 days prior to experiments. ATG7 
knockdown was confirmed by western blot. 
 
Morphologic examination  
Cells were cytospun onto glass slides and stained with Rapi-Diff (Braidwood 
Laboratories 22007, 22008, 22009) according to product guidelines. 
Morphology was examined using an Olympus DP70 digital microscope (Mason 
Technology, Dublin, Ireland). 
 
Western blotting  
Cellular protein extracts were lysed in modified RIPA buffer (50 mM TrisHCl - pH 
7.4, 150 mM NaCl, 0.25% sodium deoxycholate, 1% Igepal, 1 mM EDTA, 1x 
Pefabloc, 1x Protease inhibitor cocktail, 1 mM Na3VO4, 1 mM NaF). Protein 
samples were separated on NuPAGE 4-12%, Bis-Tris gels (Invitrogen NP0322) 
and electrophoretically transferred onto PVDF membranes (Invitrogen 
IB401001). Primary antibodies were: anti-CD11b (Abcam ab52478), anti-
LC3A/B (MBL PD014), anti-LC3B (Novus Biologicals 600-1384), anti-GABARAP 
(Abgent AP1821a), anti-GABARAPL2/GATE-16 (Abgent AP1822d) and anti-
ATG7 (Cell Signaling 2631). Proteins were visualized using relevant IR-DYE 
secondary antibodies and quantified on the Odyssey IR imaging system (Li-Cor, 
Cambridge, UK).  
 
Flow cytometry assays  
Autophagy: Live cells were stained with the Cyto-ID Autophagy Detection Kit 
(Enzo Life Sciences Exeter, UKENZ-51031) according to product protocol.  
Differentiation: CD11b - live cells were incubated for 30 min with PE-conjugated 
anti-CD11b antibody (eBioscience 12-0118 or Immunotools #21279114) in 1% 
albumin/phosphate buffered saline (PBS), and washed with PBS prior to analysis.  
CellROX Oxidative Stress Assay: To assess reactive oxygen species (ROS) 
production, cells were stained with CellRox deep red oxidative stress reagent (5 
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µM) (Molecular probes C10422) at 37 ˚C for 30 min following stimulation with 
phorbol 12-myristate 13-acetate (PMA) (50 ng/ml) (Sigma P1585) in complete 
medium. This cell permeable reagent is non-fluorescent while in a reduced state 
and upon oxidation, emits fluorescence at 665 nm. Fluorescence was detected 
using a BD-LSRII flow cytometer (BD Biosciences, Oxford, UK). Data analysis and 
histogram overlays were performed on FlowJo software.  
 
Colony growth assays  
Cells (5.0 x 104 cells/ml) were seeded into methylcellulose media (Stem Cell 
Technologies - MethoCult H4034). At day 10, cells were resuspended in warm 
RPMI and counted on a Chemometec nucleocounter.  
 
Quantitative PCR analysis 
RNA extraction was performed using the miRCURY RNA Isolation Kit from 
Exiqon (Vedbaek, Denmark) according to the manufactures description. RNA 
was reverse-transcribed using the masterscript kit purchased from 5prime 
(Hilden, Germany). Quantitative PCR analysis of CEBPε and GSF3R mRNA was 
performed using TaqMan® reagents and the StepOnePlus qPCR system (Applied 
Biosystems, Zug, Switzerland). Raw Ct values were normalized to HMBS and to 
the untreated control of day 3 (∆∆Ct method). Gene Expression Assays for CEBPE 
and CSF3R were HHs00357657_m1 and Hs00167918_m1, respectively (Applied 
Biosystems, Rotkreuz, Switzerland). HMBS primer and probes have been 
described previously [24].  
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Results 
Autophagy is upregulated during ATRA-induced APL cell differentiation. 
We investigated autophagic activity during the myeloid differentiation of APL 
cells. Human NB4 cells (PML-RARα +ve APL) were induced to differentiate along 
a granulocytic lineage with therapeutic doses of ATRA (1 μM), administered for 4 
days. Morphologically, ATRA treated cells have increased nuclear lobulation and 
a decreased nuclear to cytoplasmic (N:C) ratio characteristic of maturing 
granulocytes (Figure S1A). Differentiation was confirmed by the detection of the 
granulocyte surface marker CD11b by western blotting (Figure S1B) and by flow 
cytometry (Figure S1C).  
Autophagy is characterized by the accumulation of double-membraned 
vesicles within the cell cytoplasm. Subsequent fusions events with endosomes 
and lysosomes can often result in a vesicular morphology, detectable with light 
microscopy. Coincident with differentiation, we detected a progressive increase 
in cytoplasmic vesiculation in ATRA treated NB4 cells (Figure 1A, upper panels, 
arrows). Serial blood samples were collected from two newly diagnosed APL 
patients receiving in vivo ATRA therapy. Peripheral blood mononuclear cells 
(PBMCs) obtained from these patients also showed a progressive increase in 
cytoplasmic vesiculation visible from day 1 of ATRA treatment, suggestive of 
modulation of trafficking systems or autophagic activity (Figure 1A, middle and 
lower panels, arrows).  
In order to distinguish autophagy, we examined levels of a known marker 
LC3B. LC3B-I becomes conjugated to phosphatidylethanolamine (PE) to form 
LC3B-II, which is incorporated into autophagosome membranes. Other members 
of the ATG8 family of proteins, GABARAP and GATE-16/GABARAPL2,  can also be 
incorporated into autophagosomes [14]. As differentiation proceeded, a decrease 
in LC3B-I protein levels was observed at day 1 by western blot. An increased 
level of LC3B-II was observed by day 2 and this was further enhanced in the 
presence of the lysosomal protease inhibitors E64d and pepstatin, both of which 
prevent autophagosomal turnover (Figure 1B). We detected increased GABARAP 
and GATE-16 levels, from day 2, with GATE-16 proving to be the most specific 
protein marker (Figure 1B), consistent with previously published data [25]. 
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We then quantified autophagic activity by flow cytometry using the Cyto-
ID assay, which fluorescently tags autophagosomes [26]. A 1.8-fold increase in 
mean fluorescence intensity was detected in ATRA treated NB4 cells at day 3 
(Figure 1C). Together, these data suggest that autophagic activity is increased 
during the ATRA-mediated granulocytic differentiation of APL cells. 
 
Pharmacologic inhibition of autophagy attenuates the ATRA-induced 
differentiation of APL cells. 
We then examined whether pharmacological inhibition of autophagy would 
interfere with in vitro leukemic cell differentiation. The anti-malarial compound 
chloroquine raises lysosomal pH, inhibiting the activity of resident enzymes and 
thus impeding completion of autophagy [27]. NB4 cells were incubated for four 
days with chloroquine in the presence or absence of ATRA. While chloroquine 
alone had little effect on NB4 cells, cells co-treated with ATRA and chloroquine 
displayed increased cytoplasmic vesiculation (Figure 2A, arrows), along with 
increased levels of LC3B-II protein (Figure 2B), consistent with impaired 
autophagosome degradation. Morphologically granulocytic differentiation 
appeared stunted in co-treated cells (Figure 2A) and protein levels of CD11b 
were decreased from day 2 compared to cells treated with ATRA alone, 
consistent with attenuated differentiation (Figures 2B & 2C).  
 We observed a similar effect on differentiation when NB4 cells were 
treated with ATRA in the presence of 3-methyladenine (3-MA), a well-
established inhibitor of early autophagy. 3-MA inhibits class-III 
phosphatidylinositol 3-kinase (PI3K) – a positive regulator of autophagy 
initiation [28]. Treatment of NB4 cells with ATRA alone for 4 days induced LC3B 
II accumulation. However, the addition of 3-MA to block initiation, attenuated 
this effect (Figure 2D). Co-treatment resulted in significantly lower CD11b 
expression than treatment with ATRA alone (Figure 2E). These findings indicate 
that inhibition of autophagy with pharmacologic agents attenuates the ATRA-
mediated differentiation of APL cells and suggest that the process of autophagy 
may be an important mediator of granulocytic differentiation.  
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ATG7 is required for effective ATRA-mediated APL cell differentiation. 
We then assessed whether a known autophagy regulator, ATG7, was important 
for granulocytic differentiation of APL cells. ATG7 was depleted by lentiviral-
mediated shRNA knockdown in NB4 cells. Knockdown in two distinct clones 
(shATG7_1 & shATG7_2) was evaluated at the protein level under basal 
conditions and following pharmacologic autophagy induction to ensure that the 
protein could be effectively depleted when autophagy is induced. Rapamycin 
directly inhibits mTOR, a master negative regulator of autophagy [29]. Lithium 
chloride (LiCl) lowers cytosolic inositol 1,4,5-triphosphate (IP3) levels and is a 
potent pharmacological inducer of autophagy [30]. Following treatment for 24 
hours with either lithium or rapamycin, the ATG7-knockdown NB4 cells 
displayed reduced ATG7 expression (Figure 3A), decreased cytoplasmic 
vesiculation (Figure S2A), and no evidence of autophagy activation as assessed 
by flow cytometric Cyto-ID assay (Figure S2B). Thus, genetic inhibition of ATG7 
successfully reduced the ability of NB4 cells to induce autophagy. 
 Knockdown of ATG7 significantly impaired the granulocytic 
differentiation of NB4 cells following three days of ATRA treatment (Figure 3B, 
red overlays), with reduced CD11b expression when compared to ATRA treated 
scrambled controls (Figure 3B, blue overlays) and reduced morphological 
evidence of maturation (Figure 3C). These data suggest that competent 
autophagy is required for successful ATRA-induced differentiation of APL cells. 
 
Lithium chloride promotes ATRA-induced autophagy in non-APL, differentiation-
resistant myeloid leukemic cells. 
We then evaluated if autophagy induction could be achieved pharmacologically 
in AML cells that lack the PML-RARα fusion oncogene. HL60-Diff-R cells, an 
ATRA-resistant variant of the promyeloblastic leukemic cell line HL60, were 
treated with lithium or rapamycin. Lithium treatment caused a significant 
increase in GATE-16 protein expression, over four days of treatment, consistent 
with increased autophagy. In contrast, rapamycin caused a more moderate 
elevation in GATE16  (Figure 4A).  
  Analysis of autophagy at day 3, using the Cyto-ID assay in HL60-Diff-R 
cells showed moderate staining with lithium alone (Figure 4B (i), blue overlay).  
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Notably, a striking increase in Cyto-ID staining was seen in cells treated with the 
combination of ATRA and lithium, indicative of increased levels of 
autophagosomes (Figure 4B (i), green overlay). In contrast, a more modest 
increase in Cyto-ID staining was achieved with rapamycin in combination with 
ATRA (Figure 4B (ii), green overlay). Similar data were collected on day 4 
[Figure 4B (iii) & (iv)], with only the lithium & ATRA treatment showing a 
significant increase in Cyto-ID staining. Analysis of mean fluorescent intensity 
from three independent experiments is presented to the right of Figure 4B.  The 
effect of lithium and ATRA treatment on additional autophagy markers GATE16, 
GABARAP and LC3II was also evaluated at days 3 and 4 of differentiation [Figure 
4C (i) - (iii)]. The combination of lithium and ATRA shows strong elevation of 
GATE16. GABARAP is marginally increased on day 3, but not on day 4. LC3II 
levels are higher in all combination treatments compared to single treatments. 
Collectively these data suggest augmentation of autophagy in the lithium & ATRA 
treated cells. 
 
Lithium chloride promotes ATRA-mediated differentiation of non-APL, 
differentiation-resistant myeloid leukemic cells. 
We then evaluated if the advancement in autophagy seen with lithium 
could promote ATRA-mediated differentiation in the non-APL ATRA resistant 
AML cells.  HL60-Diff-R cells failed to successfully differentiate when treated 
with a therapeutic concentration of ATRA alone for three days (Figure 5A, red 
overlay). However, co-treatment of these cells with ATRA and lithium resulted in 
a significant increase in CD11b protein expression at day 3 (Figure 5A, green 
overlay), with quantitation of triplicate data shown to the right (p = 0.006). 
Expression of additional differentiation markers, GCSFR and CEBPε was also 
analyzed by RT-qPCR. Both markers were significantly elevated at day 3 (p = 0.0018 
and 0.0004 respectively) in the combined ATRA and lithium treated cells (Figure 5B 
and C).  
Differentiation was also assessed by quantitating the production of reactive 
oxygen species (ROS) in ATRA or lithium treated cells following stimulation with 
PMA. This would be indicative of functional maturation in differentiating cells. 
Figure 5D shows a significant elevation of ROS production in 31 % of cells co-treated 
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with lithium and ATRA for three days, compared to 2.4 and 23.9 % of cells treated 
with ATRA or lithium alone. Collective mean data is shown to the right. 
 Analysis of morphology indicated that HL60-Diff-R cells failed to 
successfully differentiate when treated with therapeutic concentrations of ATRA 
alone for four days (Figure 5E, lower left panel). In contrast, in the presence of 
lithium, morphological changes were consistent with early granulocytic 
differentiation (Figure 5E, lower right panel, arrows indicate lobed/crested 
nuclei). 
 The proliferative capacity of HL60-Diff-R cells following drug treatment 
was evaluated by removing cells from treated media at day 2 and culturing equal 
cell numbers in methylcellulose media for 10 days to assess cell numbers. At 
assay completion, decreased cell numbers were observed following co-treatment 
with ATRA and lithium, consistent with possible arrest or termination of 
malignant proliferative signaling (Figure 5F).  
These data indicate that combination treatment with ATRA and lithium 
potentiates differentiation of non-APL AML cells and may therefore be of 
potential therapeutic benefit.  
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Discussion 
In this study, we demonstrate that autophagy is upregulated during ATRA-
mediated granulocytic differentiation of APL cells. This is associated with an 
increase in LC3B-II and GATE-16 levels, consistent with their involvement in 
autophagosome formation [14]. We show that inhibition of autophagy, either 
pharmacologically or through targeted genetic knockdown of ATG7, impedes 
ATRA-mediated differentiation. Thus, we propose that the process of autophagy 
is an important mediator of ATRA’s effects on APL cells, providing further 
support to recent data on leukemic cell differentiation [20-22, 31]. 
 ATG7 is a key enzyme in autophagic pathways, acting in both of the 
conjugation steps involved in autophagosome formation – the conjugation of 
ATG5 and ATG12, and the conjugation of ATG8 family members to 
phosphatidylethanolamine (PE) [18]. Previous studies in other cell and in vivo 
models have shown successful inhibition of autophagy by knockdown/deletion 
of ATG7 [32]. Within the hematopoietic system, the importance of ATG7 has been 
demonstrated in normal hematopoietic stem cell renewal, quiescence and 
remodeling, while also being involved in the differentiation of erythrocytes, 
lymphocytes and mast cells [13]. The importance of other autophagy regulators 
such as ULK1, ATG5, PI3KC3, SQSTM1 [20], BECN1 [19], DRAM-1 [31] and GATE-
16 [21] for APL cell differentiation has been evaluated; however, the effect of 
ATG7 knockdown has not previously been examined. Our study thus establishes 
a novel and important role for ATG7 in APL differentiation and by inference, 
response to differentiation therapy.  
 It is now broadly accepted that ATRA exerts dual effects on APL cells – 
overcoming the repressive transcriptional effects of the PML-RARα oncoprotein 
and increasing its degradation [6]. Using synthetic retinoids capable of activating 
transcription but not protein degradation, these effects have been uncoupled, 
showing that while differentiation can occur in the absence of proteolysis, PML-
RARα elimination is necessary to achieve long-term disease control [5]. 
Operating without steric limitations, autophagy is the primary pathway available 
to cells for degrading large aggregated proteins. The chimeric PML-RARα protein 
(MW 110 kDa), is more prone to aggregation than either PML or RARα alone [22]. 
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This leads to the formation of a large multimeric complex (669 kDa)[33], which 
requires functioning autophagy for its degradation [20, 22]. While our data 
would be consistent with autophagy promoting PML-RARα proteolysis, we also 
show that lithium chloride, an autophagy inducer, potentiates the ATRA-
mediated granulocytic differentiation of AML cells that do not carry an abnormal 
RARα fusion protein. Thus, it is likely that autophagy plays a role in the extensive 
cellular remodeling that occurs in differentiating cells and is not solely involved 
in oncoprotein clearance. 
 There is now increasing data supporting a role for autophagy in cellular 
differentiation [15]. Within the hematopoietic system, murine studies have 
elucidated a critical role for autophagy in the removal of intracellular organelles 
from developing reticulocytes. Indeed, interference with several important 
autophagy genes (ULK1, ATG7, BNIPL3 or FIP200) results in severe red cell 
defects and anemia [17, 34]. Autophagy also participates in the differentiation of 
both B- and T-lymphocytes [35], plasma cells [16] and monocytes [36]. Despite 
the confounding presence of an abnormal fusion oncoprotein, the ATRA-
mediated differentiation of APL cells in culture has long been used as a model for 
normal myelopoiesis [37]. Our study performed on a leukemic cell line model 
may have broader application, also suggesting a role for autophagy in normal 
myelopoiesis. It is possible that defects in autophagy may contribute to the 
differentiation block seen in malignancies such as AML. Conditional deletion of 
the ATG7 gene in the murine hematopoietic system results in an abnormal 
myeloid proliferation with dysplasia which is ultimately fatal – a condition very 
closely resembling AML [18]. In this study, using the promyeloblastic ATRA-
resistant HL60-Diff-R cell line, which does not carry the PML-RARα oncoprotein 
characteristic of APL, we show that treatment with lithium chloride in 
combination with ATRA promoted granulocytic differentiation, suggesting that 
induction of autophagy may overcome the differentiation block in these cells. 
 Lithium has shown long-standing clinical efficacy in the treatment of 
mood disorders. Mechanistically, the lithium ion competitively inhibits 
magnesium binding sites on dependent enzymes [38]. Following observations 
that patients undergoing lithium therapy developed granulocytosis [39], in vitro 
studies in the early 1990s showed that combinations of lithium with ATRA 
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induced the differentiation of human myeloid leukemic cell lines [40]. This effect 
was attributed to either increased RARα pools or to the inhibitory actions of 
lithium on glycogen synthase kinase 3β (GSK3β), a serine/threonine kinase with 
well-characterized roles in differentiation [38, 41-43]. Lithium-induced 
autophagy has been associated with neuroprotective effects in conditions that 
are attributable to the accumulation of abnormal mutant proteins e.g. huntingtin 
in Huntington’s disease and α-synuclein in Parkinson’s disease [38, 44]. 
Lithium’s effects on autophagy in neuronal cells have been reported to be 
mediated by inhibition of the enzyme inositol monophophatase (IMP) and 
depletion of free inositol [30]. Lithium has also been reported to augment 
signaling through the cAMP pathway (reviewed in [45]). Interestingly, a recent 
study found that augmentation of this pathway with 8-CPT-cAMP, upregulated 
p62/SQSTM1 and LC3 and promoted ATRA induced differentiation of the 
resistant cell line NB4-LR1 [46].  
It is therefore important to acknowledge that while lithium is an 
autophagy inducer, the pro-differentiation effects of lithium observed in our 
experiments are likely to be multi-factorial, with input from several signaling 
pathways. However, given our data and those of others supporting an important 
role for autophagy in differentiation, we propose that autophagy induction by 
lithium, may contribute to its pro-differentiation effects, and this has not been 
previously recognized in the literature.  
 Autophagy is a known cellular response to stress - enabling survival in 
times of nutrient depletion or oxidative stress [47]. However, autophagy has also 
been linked to the induction of a form of programmed cell death distinct from 
classical apoptosis [48]. The role of autophagy in cancer is complex and appears 
to be context-dependent.  While in normal cells autophagy has a tumor-
suppressive function, cancer cells are often capable of using survival autophagy 
to sustain their metabolism in hypoxic or nutrient-depleted environments [49]. 
Indeed, cancer cells have been observed to upregulate autophagy in response to 
chemotherapeutic stress and studies of several cancer models – including 
chronic myeloid leukemia [50], have shown that autophagy inhibition increases 
chemoefficiency [48, 51].  As a result, several clinical trials, combining the 
autophagy inhibitor chloroquine or its sister drug hydroxychloroquine, with 
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conventional chemotherapy are currently underway in both solid and 
hematologic malignancies [52]. Conversely, studies in hematologic malignancies 
have shown that several anti-tumor agents promote autophagic cell death, and 
that this is critical to their efficacy [48, 53]. Our study supports the concept that 
autophagy induction may be of clinical benefit through promoting terminal 
differentiation and subsequent cell death. Further studies with AML clinical 
samples and other autophagy inducers are warranted. 
In summary, this study suggests that autophagy is a critical component of 
ATRA’s differentiating effects in APL and that pharmacologic autophagy 
induction in this context may potentiate the ATRA-mediated differentiation of 
non-APL AML cells. We expect that such a combination therapy would likely be 
minimally cytotoxic to normal cells and would be well tolerated by elderly 
patient populations, providing at least transient disease control in the absence of 
chemotherapy. The exact mechanisms through which ATRA activates autophagy 
remain to be elucidated and we expect that future studies will address this issue 
so that we can understand how best to target this process for patient benefit.  
 
Conclusion  
This study demonstrates a key role for autophagy in myeloid differentiation. 
Importantly, these data show that differentiation can be achieved in ATRA 
resistant AML cells, by co-treatment with lithium.  Lithium induces autophagy 
and diminishes colony regrowth. As pharmacologically overcoming the 
differentiation block in AML would be a major therapeutic advance, the 
possibility of achieving this with autophagy inducers is an attractive area for 
future intervention.  
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Figure 1. Autophagy is increased during the ATRA-mediated differentiation 
of APL cells. NB4 cells were treated with 1 μM ATRA for the times indicated in 
the presence or absence of lysosomal inhibitors: E64d (5 μM) and pepstatin A (1 
μM). These experiments were performed a minimum of three times with very 
similar data. Peripheral blood mononuclear cells (PBMCs) were isolated from 
serial blood samples drawn from two APL patients undergoing in vivo therapy. 
Both patients received ATRA at day 0 and idarubicin at day 2. Peripheral white 
cell counts (WCCs) at diagnosis were 3.2 x 109/L for patient #1 and 1.1 x 109/L 
for patient #2. In both patients the leukemic clone carried a confirmed t(15;17) 
translocation and displayed a characteristic APL immunophenotype (HLADR-, 
CD13+, CD33+, CD117+, CD11c-). (A) Cytoplasmic vesiculation as a morphologic 
feature of autophagy during granulocytic differentiation was examined by light 
microscopy in ATRA treated NB4 cells and primary APL patient PBMCs 
(arrows)(40x magnification). (B) Autophagy and autophagic flux were measured 
in NB4 cells by evaluating protein levels of LC3-I/II (MBL), GATE-16 (Abgent) 
and GABARAP (Abgent) in whole cell protein lysates. All bands were quantified 
using the Odyssey Infrared Imaging System (Li-COR), normalized to β-actin and 
presented as integrated intensities in the right hand panels. A single representative 
actin blot is shown. (C) Live NB4 cells were stained using the Cyto-ID autophagy 
detection kit and levels of autophagy were assessed by flow cytometry. A 
representative image is shown.  
Figure 2. Effects of pharmacologic autophagy inhibition on ATRA-induced 
APL cell differentiation. NB4 cells were treated for four days with 1 μM ATRA 
alone or in combination with an autophagy inhibitor: either chloroquine (10 μM) 
or 3-methyladenine (3-MA) (5 mM). (A) Differentiation morphology and 
cytoplasmic vesiculation were examined by light microscopy at day 4 in cells 
treated with ATRA and chloroquine (40x magnification). ATRA treated cells 
display increased nuclear lobulation and a decreased nuclear:cytoplasmic (N:C) 
ratio consistent with differentiation, while these changes are reduced in cells co-
treated with ATRA and chloroquine. Increased vesiculation observed in co-
treated cells represents an accumulation of autophagosomes due to increased 
production with a block in terminal autophagosome turnover (arrows). (B) 
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Inhibition of terminal ATRA-induced autophagy by chloroquine was measured 
by quantifying LC3-I/II protein levels (MBL). Differentiation was assayed by 
measuring total CD11b protein expression on western blot (Abcam). All bands 
were quantified using the Odyssey Infrared Imaging System (Li-COR), normalized to 
β-actin and presented as integrated intensities, in the right hand panel. Data are 
representative of three independent experiments. (C) Median fluorescence 
intensity (MFI) of surface CD11b expression at day 4 was used as a marker of 
differentiation (Immunotools). Data are presented as mean fold induction of 
CD11b compared to untreated cells for three independent experiments   S.E.M  
(*P < 0.05). (D) Western blot analysis of LC3 at day 4 in ATRA alone and ATRA + 
3-MA treated cells (Novus Biologicals), with GAPDH used as a loading control. 
(E) Surface CD11b expression at day 4 was measured by flow cytometry 
(Immunotools) and analyzed as in (C) (*P < 0.05). 
Figure 3.  Effects of genetic ATG7 knockdown on ATRA-induced APL cell 
differentiation. ATG7 was knocked down in NB4 cells using lentiviral 
transduction of target-specific shRNA. (A) Two independent ATG7 knockdown 
cell lines (shATG7_1 and shATG7_2), wild type NB4 cells (WT), and NB4 cells 
transduced with an off-target scrambled shRNA (shSCR) were treated for 24 
hours with either 20 mM lithium chloride (LiCl) or 400 nM rapamycin (Rap) to 
induce autophagy. Successful knockdown was confirmed by measurement of 
ATG7 protein levels by western blot in untreated and treated cells (Cell 
Signalling), with quantification against β-actin (n=2). (B) Two knockdown NB4 
clones and scrambled controls were seeded at 2 x 105 cells/mL and treated with 
ATRA (1 μM) for 3 days. Differentiation was assessed at day 3 by measurement 
of surface CD11b expression (eBioscience) (n=2). Grey filled histograms are 
untreated SCR controls, blue histograms are SCR treated with ATRA and red 
histograms show reduced differentiation in the ATG7 knockdown clones (C) 
Morphologic analysis by light microscopy at day 3 in ATG7 knockdown cell lines 
as assessed by nuclear shape and N:C ratio (40x magnification).  
Figure 4. Effects of lithium or rapamycin alone and combined with ATRA on 
autophagy in ATRA-resistant non-APL AML cells. (A) HL60-Diff-R cells were 
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treated with either lithium chloride (LiCl) (10 mM) or rapamycin (Rap) (400 nM). 
The induction of autophagy by lithium and rapamycin in HL60-Diff-R cells was 
measured by western blotting for GATE-16 protein levels at indicated times 
(Abgent). All bands were quantified using the Odyssey Infrared Imaging System (Li-
COR), normalized to β-actin and presented as integrated intensities above western 
blots. This experiment was repeated three times with similar data. (B) HL60-Diff-
R cells, treated for three and four days, were stained with Cyto-ID autophagy 
detection kit and levels of autophagy were quantified by flow cytometry. Single 
representative overlay histograms of cells treated with lithium (i) and (iii) or 
rapamycin (ii) and (iv) are shown.  Histogram data for both lithium and 
rapamycin treated cells +/- ATRA (1 µM) are presented as mean fluorescence 
intensity  S.E.M to the right. (n=3)(*** P < 0.0001, ** p < 0.01). (C) Induction of 
autophagy was further confirmed by western blotting for GATE16 (i), GABARAP 
(ii) and LC3 I/II (iii) levels. All bands were quantified using the Odyssey Infrared 
Imaging System (Li-COR), normalized to β -actin and presented as integrated 
intensities, relative to their respective controls. 
 
Figure 5. Effects of lithium combined with ATRA on differentiation of ATRA-
resistant non-APL AML cells. (A) HL60-Diff-R cells were treated with ATRA (1 
µM) in the presence or absence of lithium chloride (LiCl) (10 mM) for three days. 
The induction of differentiation was assessed by measuring surface CD11b 
(eBioscience) by flow cytometry. A single representative overlay histogram is 
shown, with mean fluorescence intensity  S.E.M presented to the right (n=4). 
(B) & (C) GCSF3R and CEBPε qPCR analysis of HL60-Diff-R cells treated as 
indicated for three days. Raw Ct values were normalized to HMBS and data are 
shown as n-fold induction compared to the untreated control cells. (D) Reactive 
oxygen species (ROS) production was assessed with CellROX oxidative stress 
assay in cells treated for three days with ATRA (1 µM) without and with lithium 
(10 mM). The percentage of ROS positive cells is presented as mean  S.E.M to 
the right. (E) Morphologic features of granulocytic differentiation were assessed 
at day 4 by light microscopy (40x magnification). Arrows indicate cells with 
features of early granulocytic differentiation. (F) Cells were removed from their 
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indicated drug treatments at day 2 and cultured in triplicate at a seeding density 
of 5 x 104 cells/mL in drug-free methylcellulose medium. A cell count was 
performed at day 10 to assess post-treatment cell proliferation (n=3).  (*** p < 
0.0005, ** p < 0.005). 
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